Commentary: Evaluating Oversight of Human Drugs and Medical Devices

Journal of Law, Medicine and Ethics 37 (4):629-632 (2009)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.1111/j.1748-720x.2009.00436.x

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,227

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Commentary: Evaluating Oversight of Human Drugs and Medical Devices.Susan Bartlett Foote - 2009 - Journal of Law, Medicine and Ethics 37 (4):629-632.
Commentary: Public Outreach by the FDA: Evaluating Oversight of Human Drugs and Medical Devices.Mark S. Frankel - 2009 - Journal of Law, Medicine and Ethics 37 (4):625-628.
Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology.Jordan Paradise, Alison W. Tisdale, Ralph F. Hall & Efrosini Kokkoli - 2009 - Journal of Law, Medicine and Ethics 37 (4):598-624.
Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology.Jordan Paradise, Alison W. Tisdale, Ralph F. Hall & Efrosini Kokkoli - 2009 - Journal of Law, Medicine and Ethics 37 (4):598-624.
Commentary: Public Outreach by the FDA: Evaluating Oversight of Human Drugs and Medical Devices.Mark S. Frankel - 2009 - Journal of Law, Medicine and Ethics 37 (4):625-628.
Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences.Jordan Paradise, Susan M. Wolf, Jennifer Kuzma, Aliya Kuzhabekova, Alison W. Tisdale, Efrosini Kokkoli & Gurumurthy Ramachandran - 2009 - Journal of Law, Medicine and Ethics 37 (4):688-705.
Are patents for methods of medical treatment contrary to the ordre public and morality or "generally inconvenient"?O. Mitnovetski - 2004 - Journal of Medical Ethics 30 (5):470-475.
Commentary: Who's Afraid of the RAC? Lessons from the Oversight of Controversial Science.Jeffrey P. Kahn - 2009 - Journal of Law, Medicine and Ethics 37 (4):685-687.
Commentary: Is It Possible to Determine the Extent to Which Informational Asymmetries and Prejudice Bias Responses?Terrance Hurley - 2009 - Journal of Law, Medicine and Ethics 37 (4):594-597.
Medicolegal Conference on Medical Products, Devices and Drugs Scheduled for Boston.[author unknown] - 1976 - Journal of Law, Medicine and Ethics 4 (2):12-13.
Gene Therapy Oversight: Lessons for Nanobiotechnology.Susan M. Wolf, Rishi Gupta & Peter Kohlhepp - 2009 - Journal of Law, Medicine and Ethics 37 (4):659-684.
Evaluating the science and ethics of research on humans: a guide for IRB members.Dennis John Mazur - 2007 - Baltimore: Johns Hopkins University Press.
How safe are new medical devices?Stephen J. Humphreys - 2012 - Research Ethics 8 (1):43-48.
ASLM Conference on Medical Products, Devices and Drugs Held in Boston, June 21?22, 1976.Shirley G. Yerkes - 1976 - Journal of Law, Medicine and Ethics 4 (3):12-13.
ASLM Conference on Medical Products, Devices and Drugs Held in Boston, June 21?22, 1976.Shirley G. Yerkes - 1976 - Journal of Law, Medicine and Ethics 4 (3):12-13.

Analytics

Added to PP
2016-02-04

Downloads
20 (#770,916)

6 months
7 (#438,648)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

Add more references